Purinergic signalling pathway: therapeutic target in ovarian cancer

Egyptian Journal of Medical Human Genetics

Table 1 Purinergic receptors in cancer

S. no.	Receptor subtypes	Preferred natural ligand	Role of purinergic receptors in ovarian cancer	References
P1 Adenosine receptors [G protein coupled receptor]
1.	A1R	Adenosine	Immune activation and tumour suppression	[31, 32]
2.	A2AR	Adenosine	Immune suppression and pro-tumour effects	[33, 34]
3.	A2BR	Adenosine	Immune suppression and pro-tumour effects	[33, 34]
4.	A3R	Adenosine	Immune activation and tumour suppression	[31, 32]
P2 Purinergic receptors
1. P2X receptors [ligand-gated ion channel receptor]
1.	P2X₁	ATP	NA	NA
2.	P2X₂	ATP	NA	NA
3.	P2X₃	ATP	NA	NA
4.	P2X₄	ATP	NA	NA
5.	P2X₅	ATP	Cell differentiation	[35]
6.	P2X₆	ATP	NA	NA
7.	P2X₇	ATP	Cell differentiation	[35]
2. P2Y receptors [G-protein-coupled receptor]
1.	P2Y₁	ADP	Tumour cell proliferation	[35]
2.	P2Y₂	ATP = UTP	Tumour cell proliferation	[35]
3.	P2Y₄	UTP	NA	NA
4.	P2Y₆	UDP	NA	NA
5.	P2Y₁₁	ATP	NA	NA
6.	P2Y₁₂	ADP	EMT during cancer progression	[36]
7.	P2Y₁₃	ADP	NA	NA
8.	P2Y₁₄	UDP - glucose	NA	NA

ADP adenosine diphosphate, ATP adenosine triphosphate, EMT epithelial mesenchymal transittion, UDP uridine diphosphate, UMP uridine monophosphate, UTP uridinetriphosphate